Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyRemoxipride
Identification
- Name
- Remoxipride
- Accession Number
- DB00409 (APRD00316)
- Type
- Small Molecule
- Groups
- Approved, Withdrawn
- Description
An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.
- Structure
Structure for DB00409 (Remoxipride)
- Synonyms
- Remoxiprida
- Remoxipride
- Remoxipridum
- External IDs
- A 33547 / A-33547 / FLA 731 / FLA-731(-)
- Product Ingredients
Ingredient UNII CAS InChI Key Remoxipride hydrochloride MH4OU8RWCW 117591-79-4 SPFVHFBNXPARTR-IDMXKUIJSA-N - International/Other Brands
- Roxiam
- Categories
- Acids, Carbocyclic
- Amides
- Antipsychotic Agents
- Benzamides
- Benzene Derivatives
- Benzoates
- Bromobenzoates
- Central Nervous System Agents
- Central Nervous System Depressants
- Cytochrome P-450 CYP2D6 Substrates
- Dopamine Agents
- Dopamine Antagonists
- Nervous System
- Neurotransmitter Agents
- Psycholeptics
- Psychotropic Drugs
- Tranquilizing Agents
- UNII
- 0223RD59PE
- CAS number
- 80125-14-0
- Weight
- Average: 371.269
Monoisotopic: 370.089205259 - Chemical Formula
- C16H23BrN2O3
- InChI Key
- GUJRSXAPGDDABA-NSHDSACASA-N
- InChI
- InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1
- IUPAC Name
- 3-bromo-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2,6-dimethoxybenzamide
- SMILES
- CCN1CCC[[email protected]]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC
Pharmacology
- Indication
Remoxipride is an atypical antipsychotic once used for the treatment of schizophrenia.
- Structured Indications
- Not Available
- Pharmacodynamics
Remoxipride, a substituted benzamide, is a selective D2 receptor antagonist. It has been shown to be effective in the treatment of schizophrenia. Some antipsychotics block domapinergic receptors as well as cholinergic, noradrenergic and histaminergic receptors. Remoxipride was developed to act specifically on the dopamine D2 receptor. As a consequence, several undesired side effects can occur. Patients often feel they are not taking any antipsychotic drug. It has a potent affinity for the sigma receptor, but it is unclear whether it is a sigma agonist or antagonist. The contribution of this property to its clinical profile is unknown. Blocking the D2 dopamine receptor is known to cause relapse in patients that have achieved remission from depression, and such blocking also counteracts the effectiveness of SSRI medication.
- Mechanism of action
Remoxipride acts as an antagonist at the D2 dopamine receptor. It is believed that overactivity of dopamine systems in the mesolimbic pathway may contribute to the "positive symptoms" of schizophrenia (such as delusions and hallucinations), whereas problems with dopamine function in the mesocortical pathway may be responsible for the "negative symptoms", such as avolition, flat emotional response and alogia. Therefore, by decreasing the levels of dopamine in these pathways, it is thought that remoxipride is able to reduce the symptoms of schizophrenia, particularily the "positive symptoms".
Target Actions Organism AD(2) dopamine receptor antagonistHuman UD(4) dopamine receptor antagonistHuman UD(3) dopamine receptor antagonistHuman U5-hydroxytryptamine receptor 2A other/unknownHuman USigma non-opioid intracellular receptor 1 antagonistHuman - Absorption
Rapidly absorbed. Absolute bioavailability is 90%.
- Volume of distribution
- Not Available
- Protein binding
89-98%
- Metabolism
No active metabolites
- Route of elimination
- Not Available
- Half life
4-7 hours
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine Remoxipride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine Remoxipride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine. Experimental 3,4-Methylenedioxyamphetamine Remoxipride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine Remoxipride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine. Experimental, Illicit 7-Nitroindazole The risk or severity of adverse effects can be increased when Remoxipride is combined with 7-Nitroindazole. Experimental Abiraterone The serum concentration of Remoxipride can be increased when it is combined with Abiraterone. Approved Acepromazine The risk or severity of adverse effects can be increased when Remoxipride is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Remoxipride is combined with Aceprometazine. Approved Adipiplon The risk or severity of adverse effects can be increased when Remoxipride is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Remoxipride is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Remoxipride is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Remoxipride is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Remoxipride. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Remoxipride is combined with Allopregnanolone. Investigational Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Remoxipride. Approved, Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Remoxipride is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Remoxipride is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Remoxipride. Approved, Illicit, Investigational Amiodarone The metabolism of Remoxipride can be decreased when combined with Amiodarone. Approved, Investigational Amisulpride Remoxipride may increase the antipsychotic activities of Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Remoxipride. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Remoxipride. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Remoxipride. Approved Amperozide The risk or severity of adverse effects can be increased when Remoxipride is combined with Amperozide. Experimental Amphetamine Remoxipride may decrease the stimulatory activities of Amphetamine. Approved, Illicit, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Remoxipride. Approved, Investigational Artemether The metabolism of Remoxipride can be decreased when combined with Artemether. Approved Articaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Remoxipride. Approved Atomoxetine The metabolism of Remoxipride can be decreased when combined with Atomoxetine. Approved Azaperone The risk or severity of adverse effects can be increased when Remoxipride is combined with Azaperone. Investigational, Vet Approved Azelastine Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Remoxipride. Approved Barbital The risk or severity of adverse effects can be increased when Remoxipride is combined with Barbital. Illicit Benperidol The risk or severity of adverse effects can be increased when Remoxipride is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Benzocaine. Approved, Investigational Benzphetamine Remoxipride may decrease the stimulatory activities of Benzphetamine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Remoxipride is combined with Benzyl alcohol. Approved Betaxolol The metabolism of Remoxipride can be decreased when combined with Betaxolol. Approved, Investigational Brexpiprazole The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Remoxipride. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. Approved Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Remoxipride. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Remoxipride is combined with Bromisoval. Experimental Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Remoxipride. Approved, Investigational Bromperidol The risk or severity of adverse effects can be increased when Remoxipride is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Remoxipride. Approved Brotizolam The risk or severity of adverse effects can be increased when Remoxipride is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Remoxipride. Approved, Investigational Buprenorphine Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Bupropion The metabolism of Remoxipride can be decreased when combined with Bupropion. Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Remoxipride. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Remoxipride. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Remoxipride. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Remoxipride is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Remoxipride is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Remoxipride. Approved, Illicit, Vet Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Remoxipride. Approved Canertinib The risk or severity of adverse effects can be increased when Remoxipride is combined with Canertinib. Investigational Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Remoxipride. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Remoxipride. Approved Carfentanil The risk or severity of adverse effects can be increased when Remoxipride is combined with Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Remoxipride. Approved Celecoxib The metabolism of Remoxipride can be decreased when combined with Celecoxib. Approved, Investigational Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Remoxipride. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Remoxipride is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Remoxipride. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Remoxipride is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Chloroprocaine. Approved Chloroquine The metabolism of Remoxipride can be decreased when combined with Chloroquine. Approved, Investigational, Vet Approved Chlorphenamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Remoxipride. Approved Chlorphentermine Remoxipride may decrease the stimulatory activities of Chlorphentermine. Illicit, Withdrawn Chlorpromazine The metabolism of Remoxipride can be decreased when combined with Chlorpromazine. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Remoxipride. Approved Cholecalciferol The metabolism of Remoxipride can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cimetidine The metabolism of Remoxipride can be decreased when combined with Cimetidine. Approved, Investigational Cinacalcet The metabolism of Remoxipride can be decreased when combined with Cinacalcet. Approved Cinchocaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Cinchocaine. Approved, Vet Approved Citalopram The metabolism of Remoxipride can be decreased when combined with Citalopram. Approved Clemastine The metabolism of Remoxipride can be decreased when combined with Clemastine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Remoxipride. Approved Clobazam The metabolism of Remoxipride can be decreased when combined with Clobazam. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Remoxipride is combined with clomethiazole. Investigational Clomipramine The metabolism of Remoxipride can be decreased when combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Remoxipride. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Clonidine is combined with Remoxipride. Approved Clopenthixol The risk or severity of adverse effects can be increased when Remoxipride is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Remoxipride. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Remoxipride is combined with Clothiapine. Experimental Clotrimazole The metabolism of Remoxipride can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The metabolism of Remoxipride can be decreased when combined with Clozapine. Approved Cobicistat The serum concentration of Remoxipride can be increased when it is combined with Cobicistat. Approved Cocaine The metabolism of Remoxipride can be decreased when combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Remoxipride. Approved, Illicit Cyclizine The risk or severity of adverse effects can be increased when Cyclizine is combined with Remoxipride. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Remoxipride. Approved Cyclopropane The risk or severity of adverse effects can be increased when Remoxipride is combined with Cyclopropane. Experimental Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Remoxipride. Approved Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Remoxipride. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Dapiprazole is combined with Remoxipride. Approved Dapoxetine The risk or severity of adverse effects can be increased when Remoxipride is combined with Dapoxetine. Investigational Darifenacin The metabolism of Remoxipride can be decreased when combined with Darifenacin. Approved, Investigational Darunavir The serum concentration of Remoxipride can be increased when it is combined with Darunavir. Approved Delavirdine The metabolism of Remoxipride can be decreased when combined with Delavirdine. Approved Deramciclane The risk or severity of adverse effects can be increased when Remoxipride is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Remoxipride. Approved Desipramine The metabolism of Remoxipride can be decreased when combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Remoxipride. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Remoxipride is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Remoxipride is combined with Detomidine. Vet Approved Deutetrabenazine The risk or severity of adverse effects can be increased when Remoxipride is combined with Deutetrabenazine. Approved, Investigational Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Remoxipride. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Remoxipride is combined with Dexmedetomidine. Approved, Vet Approved Dextroamphetamine Remoxipride may decrease the stimulatory activities of Dextroamphetamine. Approved, Illicit Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Remoxipride. Approved Dextromoramide The risk or severity of adverse effects can be increased when Remoxipride is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Remoxipride is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Remoxipride is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Remoxipride. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Remoxipride is combined with Diethyl ether. Experimental Diethylpropion Remoxipride may decrease the stimulatory activities of Diethylpropion. Approved, Illicit Difenoxin The risk or severity of adverse effects can be increased when Difenoxin is combined with Remoxipride. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Remoxipride. Approved, Illicit Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Remoxipride. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydromorphine. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Remoxipride. Approved Diphenhydramine The metabolism of Remoxipride can be decreased when combined with Diphenhydramine. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Remoxipride. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Remoxipride is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Remoxipride is combined with Doramectin. Vet Approved Dosulepin The metabolism of Remoxipride can be decreased when combined with Dosulepin. Approved Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Remoxipride. Approved, Investigational Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Remoxipride is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. Approved, Illicit Dronedarone The metabolism of Remoxipride can be decreased when combined with Dronedarone. Approved Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Remoxipride is combined with Drotebanol. Experimental, Illicit Duloxetine The metabolism of Remoxipride can be decreased when combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Remoxipride is combined with Dyclonine. Approved Ecgonine The risk or severity of adverse effects can be increased when Remoxipride is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Remoxipride is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Remoxipride. Approved, Investigational Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Remoxipride. Approved, Investigational Eliglustat The metabolism of Remoxipride can be decreased when combined with Eliglustat. Approved Eltanolone The risk or severity of adverse effects can be increased when Remoxipride is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Enflurane is combined with Remoxipride. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Remoxipride. Approved, Investigational Ergoloid mesylate The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Remoxipride. Approved Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Remoxipride. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Remoxipride. Approved Escitalopram The risk or severity of adverse effects can be increased when Remoxipride is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Remoxipride. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Remoxipride. Approved, Investigational Ethanol Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remoxipride. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Remoxipride. Approved Ethotoin The risk or severity of adverse effects can be increased when Ethotoin is combined with Remoxipride. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Remoxipride is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Remoxipride is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Remoxipride is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Remoxipride. Approved Etoperidone The risk or severity of adverse effects can be increased when Remoxipride is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Remoxipride is combined with Etorphine. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Ezogabine is combined with Remoxipride. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Remoxipride. Approved Fencamfamine The risk or severity of adverse effects can be increased when Remoxipride is combined with Fencamfamine. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Remoxipride. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Fexofenadine is combined with Remoxipride. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Flibanserin is combined with Remoxipride. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Remoxipride is combined with Fluanisone. Experimental Fludiazepam The risk or severity of adverse effects can be increased when Remoxipride is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Flunarizine is combined with Remoxipride. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Remoxipride is combined with Flunitrazepam. Approved, Illicit Fluoxetine The metabolism of Remoxipride can be decreased when combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Remoxipride. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Remoxipride. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Remoxipride. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Remoxipride is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Remoxipride. Approved Fluvoxamine The metabolism of Remoxipride can be decreased when combined with Fluvoxamine. Approved, Investigational Fosphenytoin The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Remoxipride. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Remoxipride is combined with Fospropofol. Approved, Illicit, Investigational Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Remoxipride. Approved, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Remoxipride. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Remoxipride. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Remoxipride. Approved, Illicit, Investigational Gepefrine Remoxipride may decrease the stimulatory activities of Gepefrine. Experimental Gepirone The risk or severity of adverse effects can be increased when Remoxipride is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Remoxipride is combined with Glutethimide. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Remoxipride. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Remoxipride is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The metabolism of Remoxipride can be decreased when combined with Haloperidol. Approved Halothane The risk or severity of adverse effects can be increased when Remoxipride is combined with Halothane. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Remoxipride is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Remoxipride is combined with Hexobarbital. Approved Hydrocodone Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Remoxipride. Approved, Illicit Hydroxyamphetamine Remoxipride may decrease the stimulatory activities of Hydroxyamphetamine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. Approved Iloperidone The risk or severity of adverse effects can be increased when Iloperidone is combined with Remoxipride. Approved Imipramine The metabolism of Remoxipride can be decreased when combined with Imipramine. Approved Indalpine The risk or severity of adverse effects can be increased when Remoxipride is combined with Indalpine. Investigational, Withdrawn Indinavir The metabolism of Remoxipride can be decreased when combined with Indinavir. Approved Indiplon The risk or severity of adverse effects can be increased when Remoxipride is combined with Indiplon. Investigational Iofetamine I-123 Remoxipride may decrease the stimulatory activities of Iofetamine I-123. Approved Isocarboxazid The therapeutic efficacy of Remoxipride can be increased when used in combination with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Remoxipride. Approved, Vet Approved Isoniazid The metabolism of Remoxipride can be decreased when combined with Isoniazid. Approved, Investigational Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Remoxipride. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Remoxipride is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Remoxipride is combined with Ketobemidone. Approved, Investigational Ketoconazole The metabolism of Remoxipride can be decreased when combined with Ketoconazole. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Remoxipride. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Remoxipride. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Remoxipride is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Levocetirizine is combined with Remoxipride. Approved Levodopa The risk or severity of adverse effects can be increased when Levodopa is combined with Remoxipride. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Remoxipride is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Remoxipride is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Remoxipride. Approved Lidocaine The risk or severity of adverse effects can be increased when Lidocaine is combined with Remoxipride. Approved, Vet Approved Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Remoxipride. Approved, Investigational Lisdexamfetamine Remoxipride may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Lithium Lithium may increase the neurotoxic activities of Remoxipride. Approved Lofentanil The risk or severity of adverse effects can be increased when Remoxipride is combined with Lofentanil. Illicit Lopinavir The metabolism of Remoxipride can be decreased when combined with Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Remoxipride is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with Remoxipride. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Remoxipride. Approved Lorcaserin The metabolism of Remoxipride can be decreased when combined with Lorcaserin. Approved Lormetazepam The risk or severity of adverse effects can be increased when Remoxipride is combined with Lormetazepam. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Remoxipride. Approved Lumefantrine The metabolism of Remoxipride can be decreased when combined with Lumefantrine. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Remoxipride. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Remoxipride can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Manidipine The metabolism of Remoxipride can be decreased when combined with Manidipine. Approved, Investigational Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Remoxipride. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Remoxipride is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Remoxipride. Approved Medazepam The risk or severity of adverse effects can be increased when Remoxipride is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Remoxipride is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Remoxipride is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Remoxipride is combined with Melperone. Approved, Investigational Mephedrone Remoxipride may decrease the stimulatory activities of Mephedrone. Investigational Mephentermine Remoxipride may decrease the stimulatory activities of Mephentermine. Approved Mepivacaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Remoxipride. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Remoxipride is combined with Meptazinol. Experimental Mequitazine Remoxipride may increase the arrhythmogenic activities of Mequitazine. Approved Mesoridazine The risk or severity of adverse effects can be increased when Remoxipride is combined with Mesoridazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Remoxipride. Approved Methadone The metabolism of Remoxipride can be decreased when combined with Methadone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Remoxipride is combined with Methadyl Acetate. Approved, Illicit Methamphetamine Remoxipride may decrease the stimulatory activities of Methamphetamine. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Remoxipride is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Remoxipride is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Remoxipride. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Remoxipride. Approved Methotrimeprazine Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Remoxipride is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methoxyphenamine Remoxipride may decrease the stimulatory activities of Methoxyphenamine. Experimental Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Remoxipride. Approved Methylecgonine The risk or severity of adverse effects can be increased when Remoxipride is combined with Methylecgonine. Experimental Methylphenidate The risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenidate. Approved, Investigational Methylphenobarbital The risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenobarbital. Approved Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Remoxipride. Approved, Investigational Metoprolol The metabolism of Remoxipride can be decreased when combined with Metoprolol. Approved, Investigational Metyrosine Remoxipride may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Remoxipride. Approved, Illicit Midomafetamine Remoxipride may decrease the stimulatory activities of Midomafetamine. Experimental, Illicit, Investigational Midostaurin The metabolism of Remoxipride can be decreased when combined with Midostaurin. Approved, Investigational Milnacipran The risk or severity of adverse effects can be increased when Remoxipride is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. Approved, Investigational Mirabegron The metabolism of Remoxipride can be decreased when combined with Mirabegron. Approved Mirtazapine Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved MMDA Remoxipride may decrease the stimulatory activities of MMDA. Experimental, Illicit Moclobemide The risk or severity of adverse effects can be increased when Moclobemide is combined with Remoxipride. Approved, Investigational Molindone The risk or severity of adverse effects can be increased when Remoxipride is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Remoxipride. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Remoxipride. Approved Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Remoxipride. Approved, Investigational Nefazodone The risk or severity of adverse effects can be increased when Remoxipride is combined with Nefazodone. Approved, Withdrawn Nevirapine The metabolism of Remoxipride can be decreased when combined with Nevirapine. Approved Nicardipine The metabolism of Remoxipride can be decreased when combined with Nicardipine. Approved, Investigational Nilotinib The metabolism of Remoxipride can be decreased when combined with Nilotinib. Approved, Investigational Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Remoxipride. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Remoxipride. Approved, Vet Approved Norflurane The risk or severity of adverse effects can be increased when Remoxipride is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Remoxipride is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Remoxipride. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Remoxipride. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Remoxipride. Approved Ondansetron The risk or severity of adverse effects can be increased when Remoxipride is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Remoxipride is combined with Opium. Approved, Illicit Orphenadrine Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Remoxipride is combined with Osanetant. Investigational Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Remoxipride. Approved Oxethazaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Oxethazaine. Approved, Investigational Oxprenolol The risk or severity of adverse effects can be increased when Remoxipride is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Oxybuprocaine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Remoxipride. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Remoxipride. Approved, Investigational, Vet Approved Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Remoxipride. Approved Panobinostat The serum concentration of Remoxipride can be increased when it is combined with Panobinostat. Approved, Investigational Paraldehyde Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The metabolism of Remoxipride can be decreased when combined with Paroxetine. Approved, Investigational Peginterferon alfa-2b The serum concentration of Remoxipride can be decreased when it is combined with Peginterferon alfa-2b. Approved Penfluridol The risk or severity of adverse effects can be increased when Remoxipride is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Remoxipride. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Remoxipride. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. Approved Perazine The risk or severity of adverse effects can be increased when Remoxipride is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Remoxipride is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Remoxipride. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Remoxipride. Approved Phenazocine The risk or severity of adverse effects can be increased when Remoxipride is combined with Phenazocine. Experimental Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Remoxipride. Approved Phenibut The risk or severity of adverse effects can be increased when Remoxipride is combined with Phenibut. Experimental Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Remoxipride. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Remoxipride is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Remoxipride is combined with Phenoxyethanol. Approved Phentermine Remoxipride may decrease the stimulatory activities of Phentermine. Approved, Illicit Phenytoin The risk or severity of adverse effects can be increased when Phenytoin is combined with Remoxipride. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Remoxipride. Approved Pipamperone The risk or severity of adverse effects can be increased when Remoxipride is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Pipotiazine is combined with Remoxipride. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Remoxipride is combined with Piritramide. Approved, Investigational Pitolisant The metabolism of Remoxipride can be decreased when combined with Pitolisant. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Pizotifen is combined with Remoxipride. Approved Pomalidomide The risk or severity of adverse effects can be increased when Pomalidomide is combined with Remoxipride. Approved Pramipexole Remoxipride may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Remoxipride is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Remoxipride can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Prilocaine. Approved Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Remoxipride. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Procaine. Approved, Investigational, Vet Approved Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Remoxipride. Approved, Investigational Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Remoxipride. Approved, Vet Approved Promazine The metabolism of Remoxipride can be decreased when combined with Promazine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Remoxipride. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Remoxipride is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Proparacaine. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Remoxipride. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Remoxipride. Approved Proxibarbal The risk or severity of adverse effects can be increased when Remoxipride is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Remoxipride is combined with PSD502. Investigational Pseudoephedrine Remoxipride may decrease the stimulatory activities of Pseudoephedrine. Approved Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Remoxipride. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Remoxipride. Approved Quinagolide The therapeutic efficacy of Quinagolide can be decreased when used in combination with Remoxipride. Approved, Investigational Quinidine The metabolism of Remoxipride can be decreased when combined with Quinidine. Approved, Investigational Quinine The metabolism of Remoxipride can be decreased when combined with Quinine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Remoxipride is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Remoxipride. Approved, Investigational Ranolazine The metabolism of Remoxipride can be decreased when combined with Ranolazine. Approved, Investigational Rasagiline The risk or severity of adverse effects can be increased when Rasagiline is combined with Remoxipride. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Remoxipride. Approved Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Remoxipride. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Remoxipride. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Remoxipride is combined with Ritanserin. Investigational Ritobegron Remoxipride may decrease the stimulatory activities of Ritobegron. Investigational Ritonavir The metabolism of Remoxipride can be decreased when combined with Ritonavir. Approved, Investigational Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with Remoxipride. Approved Rolapitant The metabolism of Remoxipride can be decreased when combined with Rolapitant. Approved, Investigational Romifidine The risk or severity of adverse effects can be increased when Remoxipride is combined with Romifidine. Vet Approved Ropinirole Remoxipride may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Remoxipride. Approved Rotigotine Remoxipride may increase the sedative activities of Rotigotine. Approved Rucaparib The metabolism of Remoxipride can be decreased when combined with Rucaparib. Approved, Investigational Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Remoxipride. Approved Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Remoxipride. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Remoxipride. Approved, Vet Approved Selegiline The risk or severity of adverse effects can be increased when Selegiline is combined with Remoxipride. Approved, Investigational, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Remoxipride is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Remoxipride is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The metabolism of Remoxipride can be decreased when combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Remoxipride. Approved, Vet Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. Approved Stiripentol The metabolism of Remoxipride can be decreased when combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Remoxipride. Approved, Investigational Sulpiride Remoxipride may increase the antipsychotic activities of Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Remoxipride is combined with Sultopride. Experimental Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Remoxipride. Approved, Investigational Suvorexant Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Remoxipride is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. Approved Tasimelteon The risk or severity of adverse effects can be increased when Tasimelteon is combined with Remoxipride. Approved, Investigational Tedizolid Phosphate The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Remoxipride. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Remoxipride. Approved, Investigational Terbinafine The metabolism of Remoxipride can be decreased when combined with Terbinafine. Approved, Investigational, Vet Approved Tetrabenazine The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Remoxipride. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Remoxipride is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Remoxipride is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Remoxipride is combined with Tetrodotoxin. Investigational Thalidomide Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Remoxipride is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Remoxipride is combined with Thiopental. Approved, Vet Approved Thioridazine The metabolism of Remoxipride can be decreased when combined with Thioridazine. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Remoxipride. Approved Tiagabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Remoxipride. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Remoxipride is combined with Tiapride. Approved, Investigational Ticlopidine The metabolism of Remoxipride can be decreased when combined with Ticlopidine. Approved Tiletamine The risk or severity of adverse effects can be increased when Remoxipride is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Remoxipride is combined with Tilidine. Experimental Tipranavir The metabolism of Remoxipride can be decreased when combined with Tipranavir. Approved, Investigational Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Remoxipride. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Remoxipride. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Remoxipride. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Remoxipride. Approved, Investigational Tranylcypromine The metabolism of Remoxipride can be decreased when combined with Tranylcypromine. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Remoxipride is combined with Trazodone. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Remoxipride. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Remoxipride is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Remoxipride is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Remoxipride. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Remoxipride is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Remoxipride is combined with Triflupromazine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Trimipramine is combined with Remoxipride. Approved Triprolidine The risk or severity of adverse effects can be increased when Triprolidine is combined with Remoxipride. Approved Valproic Acid The risk or severity of adverse effects can be increased when Valproic Acid is combined with Remoxipride. Approved, Investigational Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Remoxipride. Approved Venlafaxine The metabolism of Remoxipride can be decreased when combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Remoxipride is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Remoxipride. Approved Vilazodone The risk or severity of adverse effects can be increased when Vilazodone is combined with Remoxipride. Approved Vinyl ether The risk or severity of adverse effects can be increased when Remoxipride is combined with Vinyl ether. Experimental Vortioxetine The risk or severity of adverse effects can be increased when Remoxipride is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Remoxipride is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Remoxipride is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Remoxipride. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziconotide is combined with Remoxipride. Approved Zimelidine The risk or severity of adverse effects can be increased when Remoxipride is combined with Zimelidine. Withdrawn Ziprasidone The metabolism of Remoxipride can be decreased when combined with Ziprasidone. Approved Zolazepam The risk or severity of adverse effects can be increased when Remoxipride is combined with Zolazepam. Vet Approved Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Remoxipride. Approved, Investigational Zolpidem Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Remoxipride. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Remoxipride. Approved Zotepine The risk or severity of adverse effects can be increased when Remoxipride is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Remoxipride. Approved, Investigational - Food Interactions
- Take without regard to meals.
References
- Synthesis Reference
- US4232037
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014553
- PubChem Compound
- 54477
- PubChem Substance
- 46508689
- ChemSpider
- 49195
- BindingDB
- 50026045
- ChEBI
- 92948
- ChEMBL
- CHEMBL22242
- Therapeutic Targets Database
- DAP000312
- PharmGKB
- PA164749051
- Wikipedia
- Remoxipride
- ATC Codes
- N05AL04 — Remoxipride
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility 74 mg/L Not Available logP 2.10 HOEGBERG,T ET AL. 1986 - Predicted Properties
Property Value Source Water Solubility 0.127 mg/mL ALOGPS logP 2.94 ALOGPS logP 2.34 ChemAxon logS -3.5 ALOGPS pKa (Strongest Acidic) 13.06 ChemAxon pKa (Strongest Basic) 8.4 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 50.8 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 90.56 m3·mol-1 ChemAxon Polarizability 36.25 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9705 Caco-2 permeable + 0.5835 P-glycoprotein substrate Substrate 0.775 P-glycoprotein inhibitor I Non-inhibitor 0.674 P-glycoprotein inhibitor II Non-inhibitor 0.6462 Renal organic cation transporter Non-inhibitor 0.5402 CYP450 2C9 substrate Non-substrate 0.868 CYP450 2D6 substrate Substrate 0.8919 CYP450 3A4 substrate Substrate 0.5728 CYP450 1A2 substrate Non-inhibitor 0.6776 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Inhibitor 0.8932 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.8309 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.5505 Ames test Non AMES toxic 0.6906 Carcinogenicity Non-carcinogens 0.8373 Biodegradation Not ready biodegradable 0.9703 Rat acute toxicity 2.8267 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.802 hERG inhibition (predictor II) Inhibitor 0.7976
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as dimethoxybenzenes. These are organic aromatic compounds containing a monocyclic benzene moiety carrying exactly two methoxy groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Methoxybenzenes
- Direct Parent
- Dimethoxybenzenes
- Alternative Parents
- 3-halobenzoic acids and derivatives / Benzamides / Phenoxy compounds / Anisoles / Benzoyl derivatives / Alkyl aryl ethers / Bromobenzenes / Aryl bromides / N-alkylpyrrolidines / Trialkylamines show 7 more
- Substituents
- M-dimethoxybenzene / Dimethoxybenzene / Halobenzoic acid or derivatives / 3-halobenzoic acid or derivatives / Benzamide / Benzoic acid or derivatives / Phenoxy compound / Anisole / Benzoyl / Phenol ether show 27 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Potassium channel regulator activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- DRD2
- Uniprot ID
- P14416
- Uniprot Name
- D(2) dopamine receptor
- Molecular Weight
- 50618.91 Da
References
- Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
- Lang AE, Sandor P, Duff J: Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45. [PubMed:8665533]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Sh3 domain binding
- Specific Function
- Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
- Gene Name
- DRD4
- Uniprot ID
- P21917
- Uniprot Name
- D(4) dopamine receptor
- Molecular Weight
- 48359.86 Da
References
- Seeman P, Corbett R, Van Tol HH: Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology. 1997 Feb;16(2):93-110; discussion 111-35. [PubMed:9015795]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- G-protein coupled amine receptor activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
- Gene Name
- DRD3
- Uniprot ID
- P35462
- Uniprot Name
- D(3) dopamine receptor
- Molecular Weight
- 44224.335 Da
References
- Christian AJ, Goodwin AK, Baker LE: Antagonism of the discriminative stimulus effects of (+)-7-OH-DPAT by remoxipride but not PNU-99194A. Pharmacol Biochem Behav. 2001 Mar;68(3):371-7. [PubMed:11325388]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Other/unknown
- General Function
- Virus receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
- Gene Name
- HTR2A
- Uniprot ID
- P28223
- Uniprot Name
- 5-hydroxytryptamine receptor 2A
- Molecular Weight
- 52602.58 Da
References
- Seeman P, Corbett R, Van Tol HH: Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology. 1997 Feb;16(2):93-110; discussion 111-35. [PubMed:9015795]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Opioid receptor activity
- Specific Function
- Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma m...
- Gene Name
- SIGMAR1
- Uniprot ID
- Q99720
- Uniprot Name
- Sigma non-opioid intracellular receptor 1
- Molecular Weight
- 25127.52 Da
References
- Lang A, Soosaar A, Koks S, Volke V, Bourin M, Bradwejn J, Vasar E: Pharmacological comparison of antipsychotic drugs and sigma-antagonists in rodents. Pharmacol Toxicol. 1994 Sep-Oct;75(3-4):222-7. [PubMed:7800667]
- Okuyama S: [Atypical antipsychotic profiles of sigma receptor ligands]. Nihon Yakurigaku Zasshi. 1999 Jul;114(1):13-23. [PubMed:10562961]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 05:33